» Articles » PMID: 32472394

An In Vitro Partial Lesion Model of Differentiated Human Mesencephalic Neurons: Effect of Pericyte Secretome on Phenotypic Markers

Overview
Journal J Mol Neurosci
Date 2020 May 31
PMID 32472394
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's disease (PD) is characterised by the progressive degeneration of dopaminergic (DA) neurons in the substantia nigra pars compacta. Post-mortem data suggests that the loss of DA markers may long precede the cell death, leaving a window to rescue the DA phenotype. Screening for potential neuroprotective or restorative therapies, however, requires that partial lesions of DA neurons can be modelled in vitro. In order to establish a partial lesion model of DA neurons in vitro, we evaluated the effects of different exposure times to 1-methyl-4-phenylpyridinium (MPP) and 6-hydroxydopamine (6-OHDA) on the cell survival and DA marker expression using DA neurons derived from the Lund human mesencephalic (LUHMES) cell line. We show that 24-h incubation with 50 μM of MPP or 6-h incubation with 100 μM of 6-OHDA leads to a significant decrease in the protein expression of DA markers without affecting overall cell death, consistent with a mild DA lesion. Using conditioned medium of human brain-derived pericytes stimulated with platelet-derived growth factor BB (PDGF-BB), we demonstrate a significant upregulation of DA markers. In conclusion, we provide an experimental model of an in vitro DA neuron partial lesion suitable to study different molecules and their potential neuroprotective or neurorestorative effects on the DA phenotype. We provide evidence that the secretome of brain pericytes stimulated via PDGF-BB/PDGFRβ affects DA marker expression and may represent one possible mechanism contributing to the neurorestoration previously observed in PD by this growth factor.

Citing Articles

Probabilistic cell seeding and non-autofluorescent 3D-printed structures as scalable approach for multi-level co-culture modeling.

Buchmann S, Enrico A, Holzreuter M, Reid M, Zeglio E, Niklaus F Mater Today Bio. 2023; 21:100706.

PMID: 37435551 PMC: 10331311. DOI: 10.1016/j.mtbio.2023.100706.


LUHMES Cells: Phenotype Refinement and Development of an MPP-Based Test System for Screening Antiparkinsonian Drugs.

Beliakov S, Blokhin V, Surkov S, Ugrumov M Int J Mol Sci. 2023; 24(1).

PMID: 36614176 PMC: 9821222. DOI: 10.3390/ijms24010733.


Insights Into the Role of Platelet-Derived Growth Factors: Implications for Parkinson's Disease Pathogenesis and Treatment.

Li D, Huang L, Zhang C, Li Q, Wang J Front Aging Neurosci. 2022; 14:890509.

PMID: 35847662 PMC: 9283766. DOI: 10.3389/fnagi.2022.890509.


A New Method for the Visualization of Living Dopaminergic Neurons and Prospects for Using It to Develop Targeted Drug Delivery to These Cells.

Blokhin V, Lavrova A, Surkov S, Mingazov E, Gretskaya N, Bezuglov V Int J Mol Sci. 2022; 23(7).

PMID: 35409040 PMC: 8998426. DOI: 10.3390/ijms23073678.

References
1.
Armulik A, Genove G, Mae M, Nisancioglu M, Wallgard E, Niaudet C . Pericytes regulate the blood-brain barrier. Nature. 2010; 468(7323):557-61. DOI: 10.1038/nature09522. View

2.
Bell R, Winkler E, Sagare A, Singh I, LaRue B, Deane R . Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron. 2010; 68(3):409-27. PMC: 3056408. DOI: 10.1016/j.neuron.2010.09.043. View

3.
Bergers G, Song S . The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol. 2005; 7(4):452-64. PMC: 1871727. DOI: 10.1215/S1152851705000232. View

4.
Boix J, Padel T, Paul G . A partial lesion model of Parkinson's disease in mice--characterization of a 6-OHDA-induced medial forebrain bundle lesion. Behav Brain Res. 2015; 284:196-206. DOI: 10.1016/j.bbr.2015.01.053. View

5.
Bove J, Perier C . Neurotoxin-based models of Parkinson's disease. Neuroscience. 2011; 211:51-76. DOI: 10.1016/j.neuroscience.2011.10.057. View